Tacrolimus Ophthalmic Solutions Recalled for Sterility Assurance Issues
Pharmacy Innovations recalls Tacrolimus ophthalmic solutions nationwide due to potential sterility assurance issues from insanitary facility conditions found during FDA inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a risk-of-harm product (sterile ophthalmic solution requiring strict sterility standards) where no injuries have been reported. Per the rubric, this qualifies for Score 3 (High). While classified as FDA Class II, the absence of reported hospitalizations precludes a Score 4.
Plain-English summary
Pharmacy Innovations is recalling multiple formulations of Tacrolimus ophthalmic solutions with concentrations of 0.03%, 0.1%, and 0.02%. The recall includes human ophthalmic solutions and veterinary formulations distributed nationwide in the United States.
An FDA inspection of the manufacturing facility at 2936 W 17th St., Erie, PA, revealed insanitary conditions. These conditions compromise the assurance that the products meet the sterility requirements essential for ophthalmic medications.
The affected products are identified by specific batch codes documented in the recall. The FDA classified this as a Class II recall due to the potential health risk from non-sterile ophthalmic solutions.
The recalled product
- Product
- TACROLIMUS 0.03% OPH SOLUTION TACROLIMUS 0.1% (1ML DROPTAINER) OPH SOLUTION TACROLIMUS -CORN OIL- 0.03% OPH SOLUTION TACROLIMUS-VET- 0.02% (10ML DROPPER) OPHTHALMIC TACROLIMUS-VET- 0.02% (15ML DROPPER) OPHTHALMIC TACROLIMUS-VET- 0.02% (5ML DROPPER) OPHTHALMIC TACROLIMUS-VET- 0.
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Ophthalmic Solution
- Hazard
- contamination
- infection-risk
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01